

Paolo Gresele

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/174960/publications.pdf>

Version: 2024-02-01

343
papers

13,842
citations

21215

62
h-index

35168

102
g-index

349
all docs

349
docs citations

349
times ranked

13741
citing authors

#	ARTICLE	IF	CITATIONS
1	Germline <i>GATA2</i> variant disrupting endothelial eNOS function and angiogenesis can be restored by c-Jun/AP-1 upregulation. <i>Haematologica</i> , 2022, 107, 1072-1085.	1.7	6
2	Platelet dysfunction in platelet-type von Willebrand disease due to the constitutive triggering of the Lyn-PECAM1 inhibitory pathway. <i>Haematologica</i> , 2022, 107, 1643-1654.	1.7	3
3	Matrix metalloproteinase-2 on activated platelets triggers endothelial PAR-1 initiating atherosclerosis. <i>European Heart Journal</i> , 2022, 43, 504-514.	1.0	27
4	F9 missense mutations impairing factor IX activation are associated with pleiotropic plasma phenotypes. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 69-81.	1.9	9
5	Multicentre evaluation of 5B9, a monoclonal anti- ϵ PF4/heparin IgG mimicking human HIT antibodies, as an internal quality control in HIT functional assays: Communication from the ISTH SSC Subcommittee on Platelet Immunology. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 252-259.	1.9	5
6	Increased plasma PCSK-9 is associated with restenosis in patients undergoing carotid endarterectomy. <i>Internal and Emergency Medicine</i> , 2022, , 1.	1.0	0
7	Vitamin B12 levels in patients with retinal vein occlusion and their relation with clinical outcome: a retrospective study. <i>Internal and Emergency Medicine</i> , 2022, 17, 1065-1071.	1.0	1
8	Vaccine-induced massive pulmonary embolism and thrombocytopenia following a single dose of Janssen Ad26.COVID.S vaccination. <i>International Journal of Infectious Diseases</i> , 2022, 116, 154-156.	1.5	11
9	Proline-rich tyrosine kinase Pyk2 regulates deep vein thrombosis. <i>Haematologica</i> , 2022, 107, 1374-1383.	1.7	7
10	The Post-thrombotic Syndrome-Prevention and Treatment: VAS-European Independent Foundation in Angiology/Vascular Medicine Position Paper. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 762443.	1.1	7
11	Pleiotropic effects of PCSK9-inhibition on hemostasis: Anti-PCSK9 reduce FVIII levels by enhancing LRP1 expression. <i>Thrombosis Research</i> , 2022, 213, 170-172.	0.8	10
12	Impact of COVID-19 and COVID-19 vaccination on high-risk patients with antiphospholipid syndrome: a nationwide survey. <i>Rheumatology</i> , 2022, 61, S1136-S1142.	0.9	13
13	Acquired haemophilia A: Italian Consensus Recommendations on diagnosis, general management and treatment of bleeding. <i>Blood Transfusion</i> , 2022, , .	0.3	5
14	Antithrombotic treatment of retinal vein occlusion: a position statement from the Italian Society on Thrombosis and Haemostasis (SISET). <i>Blood Transfusion</i> , 2022, , .	0.3	2
15	<scp>Anti-severe acute respiratory syndrome coronavirus-2</scp> adenoviral vector vaccines trigger subclinical antiplatelet autoimmunity and increase of soluble platelet activation markers. <i>British Journal of Haematology</i> , 2022, 198, 257-266.	1.2	12
16	Release of MMP-2 in the circulation of patients with acute coronary syndromes undergoing percutaneous coronary intervention: Role of platelets. <i>Thrombosis Research</i> , 2022, 216, 84-89.	0.8	1
17	Expert opinion on the use of platelet secretion assay for the diagnosis of inherited platelet function disorders: Communication from the ISTH SSC Subcommittee on Platelet Physiology. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 2127-2135.	1.9	6
18	The amazing genetic complexity of anucleated platelets. , 2022, 1, .		2

#	ARTICLE	IF	CITATIONS
19	Long-term treatment with thalidomide for severe recurrent hemorrhage from intestinal angiodysplasia in Glanzmann Thrombasthenia. <i>Platelets</i> , 2021, 32, 288-291.	1.1	1
20	Clopidogrel versus ticagrelor in high-bleeding risk patients presenting with acute coronary syndromes: insights from the multicenter START-ANTIPLATELET registry. <i>Internal and Emergency Medicine</i> , 2021, 16, 379-387.	1.0	21
21	Position paper on the safety/efficacy profile of Direct Oral Anticoagulants in patients with Chronic Kidney Disease: Consensus document of Societ� Italiana di Nefrologia (SIN), Federazione Centri per la diagnosi della trombosi e la Sorveglianza delle terapie Antitrombotiche (FCSA) and Societ� Italiana per lo Studio dell'Emostasi e della Trombosi (SISET). <i>Journal of Nephrology</i> , 2021, 34, 31-38.	0.9	6
22	Role of endothelial dysfunction in the thrombotic complications of COVID-19 patients. <i>Journal of Infection</i> , 2021, 82, 186-230.	1.7	20
23	Association of Neutrophil Activation, More Than Platelet Activation, With Thrombotic Complications in Coronavirus Disease 2019. <i>Journal of Infectious Diseases</i> , 2021, 223, 933-944.	1.9	113
24	Peripheral arterial disease has a strong impact on cardiovascular outcome in patients with acute coronary syndromes: from the START Antiplatelet registry. <i>International Journal of Cardiology</i> , 2021, 327, 176-182.	0.8	10
25	Search for SARS-CoV-2 RNA in platelets from COVID-19 patients. <i>Platelets</i> , 2021, 32, 284-287.	1.1	28
26	Trial of Rivaroxaban in AntiPhospholipid Syndrome (TRAPS): Two-year outcomes after the study closure. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 531-535.	1.9	40
27	Ischemic and bleeding risk by type 2 diabetes clusters in patients with acute coronary syndrome. <i>Internal and Emergency Medicine</i> , 2021, 16, 1583-1591.	1.0	9
28	Simoctocog Alfa (Nuwiq) in Previously Untreated Patients with Severe Haemophilia A: Final Results of the NuProtect Study. <i>Thrombosis and Haemostasis</i> , 2021, 121, 1400-1408.	1.8	14
29	ABO Blood Group and Inhibitor Risk in Severe Hemophilia A Patients: A Study from the Italian Association of Hemophilia Centers. <i>Seminars in Thrombosis and Hemostasis</i> , 2021, 47, 084-089.	1.5	3
30	Effect of First Long-Term Training on Whole Blood Count and Blood Clotting Parameters in Thoroughbreds. <i>Animals</i> , 2021, 11, 447.	1.0	10
31	Learning the Ropes of Platelet Count Regulation: Inherited Thrombocytopenias. <i>Journal of Clinical Medicine</i> , 2021, 10, 533.	1.0	14
32	Guidance on the diagnosis and management of PT�VWD: A communication from the platelet physiology subcommittee of the ISTH�REPLY to Comment on the disease� nomenclature. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 866-867.	1.9	0
33	The ISTH bleeding assessment tool as predictor of bleeding events in inherited platelet disorders: Communication from the ISTH SSC Subcommittee on Platelet Physiology. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 1364-1371.	1.9	19
34	Walking-induced endothelial dysfunction predicts ischemic cardiovascular events in patients with intermittent claudication. <i>Vascular Medicine</i> , 2021, 26, 394-400.	0.8	3
35	Platelets and Matrix Metalloproteinases: A Bidirectional Interaction with Multiple Pathophysiologic Implications. <i>Hamostaseologie</i> , 2021, 41, 136-145.	0.9	4
36	The EHA Research Roadmap: Platelet Disorders. <i>HemaSphere</i> , 2021, 5, e601.	1.2	3

#	ARTICLE	IF	CITATIONS
37	Role of Increased Lipoprotein (a) in Retinal Vein Occlusion: A Systematic Review and Meta-analysis. <i>TH Open</i> , 2021, 05, e295-e302.	0.7	13
38	Interactions of adenoviruses with platelets and coagulation and the vaccine-induced immune thrombotic thrombocytopenia syndrome. <i>Haematologica</i> , 2021, 106, 3034-3045.	1.7	24
39	Consensus recommendations on flow cytometry for the assessment of inherited and acquired disorders of platelet number and function: Communication from the ISTH SSC Subcommittee on Platelet Physiology. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 3193-3202.	1.9	20
40	Expanding the genetic spectrum of <i>TUBB1</i> -related thrombocytopenia. <i>Blood Advances</i> , 2021, 5, 5453-5467.	2.5	12
41	Management of cerebral and splanchnic vein thrombosis associated with thrombocytopenia in subjects previously vaccinated with Vaxzevria (AstraZeneca): a position statement from the Italian Society for the Study of Haemostasis and Thrombosis (SISET). <i>Blood Transfusion</i> , 2021, 19, 281-283.	0.3	24
42	Prevalence and clinical implications of eligibility criteria for prolonged dual antithrombotic therapy in patients with PEGASUS and COMPASS phenotypes: Insights from the START-ANTIPLATELET registry. <i>International Journal of Cardiology</i> , 2021, 345, 7-13.	0.8	35
43	A p.Arg127Gln variant in GPIb β LRR5 allosterically enhances affinity for VWF: a novel form of platelet-type VWD. <i>Blood Advances</i> , 2021, , .	2.5	4
44	Comparative evaluation of the fully automated HemosIL [®] AcuStar ADAMTS13 activity assay vs. ELISA: possible interference by autoantibodies different from anti ADAMTS-13. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021, 59, e193-e196.	1.4	1
45	Heparin induced thrombocytopenia: position paper from the Italian Society on Thrombosis and Haemostasis (SISET). <i>Blood Transfusion</i> , 2021, 19, 14-23.	0.3	4
46	760 Prevalence of eligibility criteria for prolonged dual antithrombotic therapy in patients with PEGASUS and COMPASS phenotypes: insights from the start-antiplatelet registry. <i>European Heart Journal Supplements</i> , 2021, 23, .	0.0	0
47	Next-generation sequencing for the diagnosis of <i>MYH9</i> : Predicting pathogenic variants. <i>Human Mutation</i> , 2020, 41, 277-290.	1.1	30
48	Eltrombopag for the treatment of inherited thrombocytopenias: a phase II clinical trial. <i>Haematologica</i> , 2020, 105, 820-828.	1.7	51
49	Development of anti-matrix metalloproteinase-2 (MMP-2) nanobodies as potential therapeutic and diagnostic tools. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2020, 24, 102103.	1.7	16
50	Validation of the ISTH/SSC bleeding assessment tool for inherited platelet disorders: A communication from the Platelet Physiology SSC. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 732-739.	1.9	64
51	Optimal Medical Therapy on Top of Dual-Antiplatelet Therapy: 1-Year Clinical Outcome in Patients With Acute Coronary Syndrome: The START Antiplatelet Registry. <i>Angiology</i> , 2020, 71, 235-241.	0.8	3
52	Novel manifestations of immune dysregulation and granule defects in gray platelet syndrome. <i>Blood</i> , 2020, 136, 1956-1967.	0.6	34
53	Guidance for the Management of Patients with Vascular Disease or Cardiovascular Risk Factors and COVID-19: Position Paper from VAS-European Independent Foundation in Angiology/Vascular Medicine. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1597-1628.	1.8	131
54	Antithrombotic prophylaxis for surgery-associated venous thromboembolism risk in patients with inherited platelet disorders. The SPATA-DVT Study. <i>Haematologica</i> , 2020, 105, 1948-1956.	1.7	7

#	ARTICLE	IF	CITATIONS
55	Antithrombotic treatment of asymptomatic carotid atherosclerosis: a medical dilemma. <i>Internal and Emergency Medicine</i> , 2020, 15, 1169-1181.	1.0	7
56	Carotid Intima-Media Thickness Progression as Surrogate Marker for Cardiovascular Risk. <i>Circulation</i> , 2020, 142, 621-642.	1.6	232
57	Eltrombopag to allow chemotherapy in a patient with MYH9-related inherited thrombocytopenia and pancreatic cancer. <i>International Journal of Hematology</i> , 2020, 112, 725-727.	0.7	6
58	The Prospective Studies of Atherosclerosis (Proof-ATHERO) Consortium: Design and Rationale. <i>Gerontology</i> , 2020, 66, 447-459.	1.4	4
59	Guidance on the diagnosis and management of platelet-type von Willebrand disease: A communication from the Platelet Physiology Subcommittee of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1855-1858.	1.9	17
60	FVIII/VWF complex displays a greater pro-haemostatic activity than FVIII preparations devoid of VWF: Study in plasma and cell-based models. <i>Haemophilia</i> , 2020, 26, e151-e160.	1.0	2
61	COVID-19 and haemostasis: a position paper from Italian Society on Thrombosis and Haemostasis (SISET). <i>Blood Transfusion</i> , 2020, 18, 167-169.	0.3	247
62	Randomized Trial of Hymovis® versus Synvisc® on Matrix Metalloproteinases in Knee Osteoarthritis. <i>Muscles, Ligaments and Tendons Journal</i> , 2020, 10, 553.	0.1	1
63	Emergency management in patients with haemophilia A and inhibitors on prophylaxis with emicizumab: AICE practical guidance in collaboration with SIBioC, SIMEU, SIMEUP, SIPMeL and SISET. <i>Blood Transfusion</i> , 2020, 18, 143-151.	0.3	22
64	Position paper on the safety/efficacy profile of direct oral anticoagulants in patients with chronic kidney disease. Consensus document from the SIN, FCSA and SISET. <i>Blood Transfusion</i> , 2020, 18, 478-485.	0.3	2
65	Gender-Related Differences in Antiplatelet Therapy and Impact on 1-Year Clinical Outcome in Patients Presenting With ACS: The START ANTIPLATELET Registry. <i>Angiology</i> , 2019, 70, 257-263.	0.8	21
66	Antiplatelet treatment in acute coronary syndrome patients: Real-world data from the START-Antiplatelet Italian Registry. <i>PLoS ONE</i> , 2019, 14, e0219676.	1.1	16
67	Effect of Body Mass Index on Ischemic and Bleeding Events in Patients Presenting With Acute Coronary Syndromes (from the START-ANTIPLATELET Registry). <i>American Journal of Cardiology</i> , 2019, 124, 1662-1668.	0.7	20
68	Inherited platelet disorders in women. <i>Thrombosis Research</i> , 2019, 181, S54-S59.	0.8	5
69	Inhibition of platelet function after ocular administration of non-steroidal anti-inflammatory drugs. <i>Thrombosis Research</i> , 2019, 175, 1-5.	0.8	4
70	Mechanisms of thrombocytopenia in platelet-type von Willebrand disease. <i>Haematologica</i> , 2019, 104, 1473-1481.	1.7	31
71	Nitric oxide-enhancing or -releasing agents as antithrombotic drugs. <i>Biochemical Pharmacology</i> , 2019, 166, 300-312.	2.0	56
72	Curated disease-causing genes for bleeding, thrombotic, and platelet disorders: Communication from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1253-1260.	1.9	56

#	ARTICLE	IF	CITATIONS
73	Eltrombopag in preparation for surgery in patients with severe <i>MYH9</i> -related thrombocytopenia. <i>American Journal of Hematology</i> , 2019, 94, E199-E201.	2.0	20
74	Fundamentals for a Systematic Approach to Mild and Moderate Inherited Bleeding Disorders: An EHA Consensus Report. <i>HemaSphere</i> , 2019, 3, e286.	1.2	43
75	Platelet function assays in diagnosis: an update. <i>Expert Review of Hematology</i> , 2019, 12, 29-46.	1.0	30
76	PCSK9 in Haemostasis and Thrombosis: Possible Pleiotropic Effects of PCSK9 Inhibitors in Cardiovascular Prevention. <i>Thrombosis and Haemostasis</i> , 2019, 119, 359-367.	1.8	58
77	Effect of statins on measures of coagulation: potential role of low-density lipoprotein receptors. <i>European Heart Journal</i> , 2019, 40, 392-392.	1.0	5
78	A phase III study comparing secondary long-term prophylaxis versus on-demand treatment with vWF/FVIII concentrates in severe inherited von Willebrand disease. <i>Blood Transfusion</i> , 2019, 17, 391-398.	0.3	18
79	A novel variant Glanzmann thrombasthenia due to co-inheritance of a loss- and a gain-of-function mutation of <i>ITGB3</i> : evidence of a dominant effect of gain-of-function mutations. <i>Haematologica</i> , 2018, 103, e259-e263.	1.7	16
80	Effect of aspirin treatment on abacavir-associated platelet hyperreactivity in HIV-infected patients. <i>International Journal of Cardiology</i> , 2018, 263, 118-124.	0.8	13
81	Anti-platelet treatments in cancer: Basic and clinical research. <i>Thrombosis Research</i> , 2018, 164, S106-S111.	0.8	16
82	Coronary and peripheral artery atherosclerosis. <i>Journal of Cardiovascular Medicine</i> , 2018, 19, e72-e74.	0.6	2
83	Epidemiology and Management of Patients With Acute Coronary Syndromes in Contemporary Real-World Practice: Evolving Trends From the EYESHOT Study to the START-ANTIPLATELET Registry. <i>Angiology</i> , 2018, 69, 795-802.	0.8	35
84	Prochemerin cleavage by factor XIa links coagulation and inflammation. <i>Blood</i> , 2018, 131, 353-364.	0.6	31
85	A dichotomy in platelet activation: Evidence of different functional platelet responses to inflammatory versus haemostatic stimuli. <i>Thrombosis Research</i> , 2018, 172, 110-118.	0.8	18
86	Of mice and men: genes relevant to thrombosis and bleeding. <i>Blood</i> , 2018, 132, 2532-2534.	0.6	0
87	Laboratory monitoring of P2Y12 inhibitors: communication from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 2341-2346.	1.9	11
88	Impact of Chronic Renal Failure on Ischemic and Bleeding Events at 1 Year in Patients With Acute Coronary Syndrome (from the Multicenter START ANTIPLATELET Registry). <i>American Journal of Cardiology</i> , 2018, 122, 936-943.	0.7	12
89	Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. <i>Blood</i> , 2018, 132, 1365-1371.	0.6	573
90	Laboratory diagnosis of clinically relevant platelet function disorders. <i>International Journal of Laboratory Hematology</i> , 2018, 40, 34-45.	0.7	24

#	ARTICLE	IF	CITATIONS
91	Bioactive lipid metabolism in platelet "first responder" and cancer biology. <i>Cancer and Metastasis Reviews</i> , 2018, 37, 439-454.	2.7	14
92	Bleeding risk of surgery and its prevention in patients with inherited platelet disorders. <i>Haematologica</i> , 2017, 102, 1192-1203.	1.7	92
93	Platelets and Airway Diseases. , 2017, , 1149-1168.		4
94	Platelet amyloid precursor protein is a modulator of venous thromboembolism in mice. <i>Blood</i> , 2017, 130, 527-536.	0.6	64
95	The Migration of Platelets and their Interaction with Other Migrating Cells. , 2017, , 337-351.		7
96	A novel mechanism regulating human platelet activation by MMP-2-mediated PAR1 biased signaling. <i>Blood</i> , 2017, 129, 883-895.	0.6	62
97	Increase of von Willebrand factor with aging in type 1 von Willebrand disease: fact or fiction?. <i>Haematologica</i> , 2017, 102, e431-e433.	1.7	15
98	Platelet "first responders" in wound response, cancer, and metastasis. <i>Cancer and Metastasis Reviews</i> , 2017, 36, 199-213.	2.7	127
99	Endothelial activation in patients with superficial vein thrombosis (SVT) of the lower limbs. <i>Thrombosis Research</i> , 2017, 157, 20-22.	0.8	4
100	Platelet-targeted pharmacologic treatments as anti-cancer therapy. <i>Cancer and Metastasis Reviews</i> , 2017, 36, 331-355.	2.7	38
101	Platelets Contribute to the Accumulation of Matrix Metalloproteinase Type 2 in Synovial Fluid in Osteoarthritis. <i>Thrombosis and Haemostasis</i> , 2017, 117, 2116-2124.	1.8	20
102	Matrix Metalloproteinases and Platelet Function. <i>Progress in Molecular Biology and Translational Science</i> , 2017, 147, 133-165.	0.9	39
103	Dipyridamole and PDE Inhibitors. , 2017, , 1283-1298.		3
104	Prevalence and predictors of dual antiplatelet therapy prolongation beyond one year in patients with acute coronary syndrome. <i>PLoS ONE</i> , 2017, 12, e0186961.	1.1	21
105	Two novel ITGA2B mutations in a Glanzmann thrombasthenia family associated with different platelet phenotypic expression. <i>Blood Transfusion</i> , 2017, 15, 487-488.	0.3	0
106	Inherited platelet function disorders. <i>Hamostaseologie</i> , 2016, 36, 265-278.	0.9	16
107	Nonmuscle Myosin Heavy Chain IIA Mutation Predicts Severity and Progression of Sensorineural Hearing Loss in Patients With MYH9-Related Disease. <i>Ear and Hearing</i> , 2016, 37, 112-120.	1.0	24
108	Cytoskeletal perturbation leads to platelet dysfunction and thrombocytopenia in variant forms of Glanzmann thrombasthenia. <i>Haematologica</i> , 2016, 101, 46-56.	1.7	50

#	ARTICLE	IF	CITATIONS
109	A high-throughput sequencing test for diagnosing inherited bleeding, thrombotic, and platelet disorders. <i>Blood</i> , 2016, 127, 2791-2803.	0.6	157
110	First Diagnosis of Hemophilia B in a Nonagenarian. <i>Journal of the American Geriatrics Society</i> , 2016, 64, 230-231.	1.3	1
111	Matrix metalloproteinase-2 enhances platelet deposition on collagen under flow conditions. <i>Thrombosis and Haemostasis</i> , 2016, 115, 333-343.	1.8	12
112	Reasons for Visits to an Emergency Center and Hemostatic Alterations in Patients with Recurrent Spontaneous Subconjunctival Hemorrhage. <i>European Journal of Ophthalmology</i> , 2016, 26, 188-192.	0.7	6
113	Platelet type von Willebrand disease and registry report: communication from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2016, 14, 411-414.	1.9	26
114	Inherited Platelet Function Disorders: Algorithms for Phenotypic and Genetic Investigation. <i>Seminars in Thrombosis and Hemostasis</i> , 2016, 42, 292-305.	1.5	52
115	Prevalence of hemostatic alterations in patients with recurrent spontaneous subconjunctival hemorrhage. <i>Clinical Chemistry and Laboratory Medicine</i> , 2016, 54, 97-103.	1.4	7
116	A review of platelet secretion assays for the diagnosis of inherited platelet secretion disorders. <i>Thrombosis and Haemostasis</i> , 2015, 114, 14-25.	1.8	82
117	Recurrent Thrombotic Events after Discontinuation of Vitamin K Antagonist Treatment for Splanchnic Vein Thrombosis: A Multicenter Retrospective Cohort Study. <i>Gastroenterology Research and Practice</i> , 2015, 2015, 1-7.	0.7	11
118	RhoA signaling through platelet P2Y1 receptor controls leukocyte recruitment in allergic mice. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 135, 528-538.e4.	1.5	60
119	Effect of substituted stilbenes on platelet function. <i>Fåterapå</i> , 2015, 105, 228-233.	1.1	30
120	Visualization of nitric oxide production by individual platelets during adhesion in flowing blood. <i>Blood</i> , 2015, 125, 697-705.	0.6	29
121	ÎllbÎ³ variants defined by next-generation sequencing: Predicting variants likely to cause Glanzmann thrombasthenia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E1898-907.	3.3	36
122	Incidence of a first thromboembolic event in carriers of isolated lupus anticoagulant. <i>Thrombosis Research</i> , 2015, 135, 46-49.	0.8	70
123	Diagnosis of inherited platelet function disorders: guidance from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 314-322.	1.9	220
124	Modeling CD40-Based Molecular Communications in Blood Vessels. <i>IEEE Transactions on Nanobioscience</i> , 2014, 13, 230-243.	2.2	48
125	Potential anti-inflammatory effects of maraviroc in HIV-positive patients: A pilot study of inflammation, endothelial dysfunction, and coagulation markers. <i>Scandinavian Journal of Infectious Diseases</i> , 2014, 46, 466-470.	1.5	9
126	<i>MYH9</i>-Related Disease: A Novel Prognostic Model to Predict the Clinical Evolution of the Disease Based on Genotype-Phenotype Correlations. <i>Human Mutation</i> , 2014, 35, 236-247.	1.1	154

#	ARTICLE	IF	CITATIONS
127	THU0194â€¦Role of Platelets in the Pathogenesis of Osteoarthritis and Biological Effects of Hyaluronic Acid: in Vivo and in Vitro Study. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 248.3-249.	0.5	1
128	Stimulation of Platelet Nitric Oxide Production by Nebivolol Prevents Thrombosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2014, 34, 820-829.	1.1	35
129	Possible incorrect genotyping of heterozygous factor V Leiden and Prothrombin 20210 gene mutations by the GeneXpert assay. <i>Clinica Chimica Acta</i> , 2014, 435, 36-39.	0.5	1
130	A novel congenital dysprothrombinemia leading to defective prothrombin maturation. <i>Thrombosis Research</i> , 2014, 134, 1135-1141.	0.8	18
131	Diagnosis of suspected inherited platelet function disorders: results of a worldwide survey. <i>Journal of Thrombosis and Haemostasis</i> , 2014, 12, 1562-1569.	1.9	139
132	Platelet diameters in inherited thrombocytopenias: analysis of 376 patients with all known disorders. <i>Blood</i> , 2014, 124, e4-e10.	0.6	112
133	Matrix metalloproteinase-2 of human carotid atherosclerotic plaques promotes platelet activation. <i>Thrombosis and Haemostasis</i> , 2014, 111, 1089-1101.	1.8	22
134	Analysis of 339 pregnancies in 181 women with 13 different forms of inherited thrombocytopenia. <i>Haematologica</i> , 2014, 99, 1387-1394.	1.7	63
135	C-reactive protein induces expression of matrix metalloproteinase-9: A possible link between inflammation and plaque rupture. <i>International Journal of Cardiology</i> , 2013, 168, 981-986.	0.8	46
136	Major bleeding in patients undergoing PCI and triple or dual antithrombotic therapy: a parallel-cohort study. <i>Journal of Thrombosis and Thrombolysis</i> , 2013, 35, 178-184.	1.0	14
137	Simulating an in vitro experiment on nanoscale communications by using BiNS2. <i>Nano Communication Networks</i> , 2013, 4, 172-180.	1.6	80
138	In vivo platelet activation and platelet hyperreactivity in abacavir-treated HIV-infected patients. <i>Thrombosis and Haemostasis</i> , 2013, 110, 349-357.	1.8	60
139	Platelet size for distinguishing between inherited thrombocytopenias and immune thrombocytopenia: a multicentric, real life study. <i>British Journal of Haematology</i> , 2013, 162, 112-119.	1.2	86
140	Impaired thrombin-induced platelet activation and thrombus formation in mice lacking the Ca ²⁺ -dependent tyrosine kinase Pyk2. <i>Blood</i> , 2013, 121, 648-657.	0.6	38
141	Reperfusion of cerebral artery thrombosis by the GPIIb/IIIa-VWF blockade with the Nanobody ALX-0081 reduces brain infarct size in guinea pigs. <i>Blood</i> , 2013, 121, 5088-5097.	0.6	61
142	AB0952â€¦Intra-articular low molecular weight hyaluronate reduces platelet influx and matrix metalloproteinase-2 levels in synovial fluid of patients with knee osteoarthritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 71, 693.3-693.	0.5	0
143	Apparent genotypeâ€¦phenotype mismatch in a patient with MYH9-related disease: When the exception proves the rule. <i>Thrombosis and Haemostasis</i> , 2013, 110, 618-620.	1.8	6
144	Platelet and endothelial activation in catastrophic and quiescent antiphospholipid syndrome. <i>Thrombosis and Haemostasis</i> , 2013, 109, 901-908.	1.8	37

#	ARTICLE	IF	CITATIONS
145	Antiplatelet agents in clinical practice and their haemorrhagic risk. <i>Blood Transfusion</i> , 2013, 11, 349-56.	0.3	20
146	Nitric oxide enhances the anti-inflammatory and anti-atherogenic activity of atorvastatin in a mouse model of accelerated atherosclerosis. <i>Cardiovascular Research</i> , 2012, 94, 428-438.	1.8	46
147	Endothelial and platelet function alterations in HIV-infected patients. <i>Thrombosis Research</i> , 2012, 129, 301-308.	0.8	69
148	Inhibitors of the Interaction Between von Willebrand Factor and Platelet GPIb/IX/V. <i>Handbook of Experimental Pharmacology</i> , 2012, , 287-309.	0.9	22
149	Higher levels of plasma matrix metalloproteinase-2 are associated with a significantly increased risk of arterial thrombosis in patients with the antiphospholipid syndrome. <i>International Journal of Cardiology</i> , 2012, 160, 149-151.	0.8	4
150	Heparin in the Prophylaxis and Treatment of Venous Thromboembolism and Other Thrombotic Diseases. <i>Handbook of Experimental Pharmacology</i> , 2012, , 179-209.	0.9	10
151	Effect on walking distance and atherosclerosis progression of a nitric oxide-donating agent in intermittent claudication. <i>Journal of Vascular Surgery</i> , 2012, 56, 1622-1628.e5.	0.6	18
152	Outside-In Signalling Generated by a Constitutively Activated Integrin α IIb β 3 Impairs Proplatelet Formation in Human Megakaryocytes. <i>PLoS ONE</i> , 2012, 7, e34449.	1.1	58
153	Alteration of Liver Enzymes Is a Feature of the Myh9-Related Disease Syndrome. <i>PLoS ONE</i> , 2012, 7, e35986.	1.1	38
154	The platelet count in EDTA-anticoagulated blood from patients with thrombocytopenia may be underestimated when measured in routine laboratories. <i>American Journal of Hematology</i> , 2012, 87, 727-728.	2.0	8
155	Contribution of matrix metalloproteinase 2 to joint destruction in group B <i>Streptococcus</i> -induced murine arthritis. <i>Arthritis and Rheumatism</i> , 2012, 64, 1089-1097.	6.7	22
156	Coinheritance of three novel FV gene mutations in a patient with a severe FV deficiency. <i>Haemophilia</i> , 2012, 18, e51-3.	1.0	6
157	In vitro effect of anti- β 2 Glycoprotein I antibodies on P-selectin expression, a marker of platelet activation. <i>Reumatismo</i> , 2012, 64, 35-9.	0.4	3
158	Acquired von Willebrand syndrome type 2A in a JAK2-positive essential thrombocythaemia -affected member of a large von Willebrand disease family with a novel autosomal dominant A1716P mutation. <i>Thrombosis and Haemostasis</i> , 2011, 105, 921-924.	1.8	4
159	Incomplete inhibition of platelet function as assessed by the platelet function analyzer (PFA-100) identifies a subset of cardiovascular patients with high residual platelet response while on aspirin. <i>Platelets</i> , 2011, 22, 179-187.	1.1	22
160	Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. <i>Blood</i> , 2011, 118, 4714-4718.	0.6	404
161	Megakaryocytes differentially sort mRNAs for matrix metalloproteinases and their inhibitors into platelets: a mechanism for regulating synthetic events. <i>Blood</i> , 2011, 118, 1903-1911.	0.6	134
162	Response: MMP-9 in platelets: maybe, maybe not. <i>Blood</i> , 2011, 118, 6471-6473.	0.6	8

#	ARTICLE	IF	CITATIONS
163	Antiplatelet therapy: phosphodiesterase inhibitors. <i>British Journal of Clinical Pharmacology</i> , 2011, 72, 634-646.	1.1	236
164	Inhibition of COX-1 activity and COX-2 expression by 3-(4-geranyloxy-3-methoxyphenyl)-2-trans propenoic acid and its semi-synthetic derivatives. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 5995-5998.	1.0	14
165	Critical limb ischemia. <i>Internal and Emergency Medicine</i> , 2011, 6, 129-134.	1.0	20
166	Effects of resveratrol and other wine polyphenols on vascular function: an update. <i>Journal of Nutritional Biochemistry</i> , 2011, 22, 201-211.	1.9	144
167	Platelets release matrix metalloproteinase-2 in the coronary circulation of patients with acute coronary syndromes: possible role in sustained platelet activation. <i>European Heart Journal</i> , 2011, 32, 316-325.	1.0	60
168	Impact of chronic antiplatelet therapy before hospitalization on ischemic and bleeding events in invasively managed patients with acute coronary syndromes: the ACUITY trial. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2011, 18, 121-128.	3.1	12
169	Impact of Tenofovir Versus Abacavir on HIV-Related Endothelial Dysfunction. <i>AIDS Patient Care and STDs</i> , 2011, 25, 567-569.	1.1	9
170	Interaction with damaged vessel wall in vivo in humans induces platelets to express CD40L resulting in endothelial activation with no effect of aspirin intake. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2011, 300, H2072-H2079.	1.5	25
171	Diagnosis of platelet-type von Willebrand disease by flow cytometry. <i>Haematologica</i> , 2010, 95, 1021-1024.	1.7	51
172	Eltrombopag for the treatment of the inherited thrombocytopenia deriving from MYH9 mutations. <i>Blood</i> , 2010, 116, 5832-5837.	0.6	141
173	Matrix metalloproteinases and peripheral arterial disease. <i>Internal and Emergency Medicine</i> , 2010, 5, 13-25.	1.0	86
174	Role of platelet activation in the cardiovascular complications associated with HIV infection: differential effect of abacavir versus tenofovir. <i>Journal of the International AIDS Society</i> , 2010, 13, P62-P62.	1.2	1
175	Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 237-242.	1.9	527
176	Endothelium, venous thromboembolism and ischaemic cardiovascular events. <i>Thrombosis and Haemostasis</i> , 2010, 103, 56-61.	1.8	71
177	Hyperglycemia-Induced Platelet Activation in Type 2 Diabetes Is Resistant to Aspirin but Not to a Nitric Oxide-Donating Agent. <i>Diabetes Care</i> , 2010, 33, 1262-1268.	4.3	40
178	Prevalence and significance of anti-prothrombin (aPT) antibodies in patients with Lupus Anticoagulant (LA). <i>Thrombosis Research</i> , 2010, 126, 150-153.	0.8	30
179	Eltrombopag for the Treatment of the Inherited Thrombocytopenia Deriving From MYH9 Mutations. <i>Blood</i> , 2010, 116, 2533-2533.	0.6	1
180	Loss of matrix metalloproteinase 2 in platelets reduces arterial thrombosis in vivo. <i>Journal of Experimental Medicine</i> , 2009, 206, 2365-2379.	4.2	80

#	ARTICLE	IF	CITATIONS
181	HIV type 1 infection, and not short-term HAART, induces endothelial dysfunction. <i>Aids</i> , 2009, 23, 589-596.	1.0	114
182	Perioperative handling of antiplatelet therapy: watching the two sides of the coin. <i>Internal and Emergency Medicine</i> , 2009, 4, 275-276.	1.0	4
183	Patients with primary antiphospholipid antibody syndrome and without associated vascular risk factors present a normal endothelial function. <i>Thrombosis Research</i> , 2009, 123, 444-451.	0.8	52
184	Assessment of the risk of bleeding in patients undergoing surgery or invasive procedures: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET). <i>Thrombosis Research</i> , 2009, 124, e6-e12.	0.8	47
185	Plasma levels of Î²2-microglobulin, a biomarker of peripheral arterial disease, are not affected by maximal leg exercise in patients with intermittent claudication. <i>Atherosclerosis</i> , 2009, 203, 38-40.	0.4	8
186	Interactions of gallic acid, resveratrol, quercetin and aspirin at the platelet cyclooxygenase-1 level Functional and modelling studies. <i>Thrombosis and Haemostasis</i> , 2009, 102, 336-346.	1.8	63
187	Dominant inheritance of a novel integrin Î³3 mutation associated with a hereditary macrothrombocytopenia and platelet dysfunction in two Italian families. <i>Haematologica</i> , 2009, 94, 663-669.	1.7	64
188	Loss of matrix metalloproteinase 2 in platelets reduces arterial thrombosis in vivo. <i>Journal of Cell Biology</i> , 2009, 187, i2-i2.	2.3	0
189	Effects of dietary protein restriction on albumin and fibrinogen synthesis in macroalbuminuric type 2 diabetic patients. <i>Diabetologia</i> , 2008, 51, 21-28.	2.9	20
190	A new case of acquired Glanzmann's thrombasthenia: Diagnostic value of flow cytometry. <i>Cytometry Part B - Clinical Cytometry</i> , 2008, 74B, 194-199.	0.7	33
191	Position of nonmuscle myosin heavy chain IIA (NMMHC-IIA) mutations predicts the natural history of MYH9-related disease. <i>Human Mutation</i> , 2008, 29, 409-417.	1.1	172
192	TAFI deficiency in liver cirrhosis: Relation with plasma fibrinolysis and survival. <i>Thrombosis Research</i> , 2008, 121, 763-768.	0.8	23
193	Potential and priming of platelet activation: a potential target for antiplatelet therapy. <i>Trends in Pharmacological Sciences</i> , 2008, 29, 352-360.	4.0	67
194	The peripheral arterial disease subgroup in the CHARISMA trial: does it tell us anything new?. <i>European Heart Journal</i> , 2008, 30, 131-132.	1.0	10
195	Ankle-brachial index measured by palpation for the diagnosis of peripheral arterial disease. <i>Family Practice</i> , 2008, 25, 228-232.	0.8	27
196	Allergen Induces the Migration of Platelets to Lung Tissue in Allergic Asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008, 177, 604-612.	2.5	147
197	Resveratrol, at Concentrations Attainable with Moderate Wine Consumption, Stimulates Human Platelet Nitric Oxide Production ³ . <i>Journal of Nutrition</i> , 2008, 138, 1602-1608.	1.3	133
198	A Comparison of Lupus Anticoagulant-Positive Patients With Clinical Picture of Antiphospholipid Syndrome and Those Without. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2007, 27, e309-10.	1.1	43

#	ARTICLE	IF	CITATIONS
199	Laboratory diagnosis and monitoring of desmopressin treatment of von Willebrand's disease by flow cytometry. <i>Haematologica</i> , 2007, 92, 1647-1654.	1.7	44
200	Endothelial dysfunction in patients with spontaneous venous thromboembolism. <i>Haematologica</i> , 2007, 92, 812-818.	1.7	92
201	Prevention by NCX 4016, a nitric oxide-donating aspirin, but not by aspirin, of the acute endothelial dysfunction induced by exercise in patients with intermittent claudication. <i>Thrombosis and Haemostasis</i> , 2007, 97, 444-450.	1.8	46
202	Platelets release active matrix metalloproteinase-2 in vivo in humans at a site of vascular injury: lack of inhibition by aspirin. <i>British Journal of Haematology</i> , 2007, 138, 221-230.	1.2	51
203	Survey of lupus anticoagulant diagnosis by central evaluation of positive plasma samples. <i>Journal of Thrombosis and Haemostasis</i> , 2007, 5, 925-930.	1.9	95
204	NCX 6560, a nitric oxide-releasing derivative of atorvastatin, inhibits cholesterol biosynthesis and shows anti-inflammatory and anti-thrombotic properties. <i>European Journal of Pharmacology</i> , 2007, 570, 115-124.	1.7	43
205	Prevention by NCX 4016, a nitric oxide-donating aspirin, but not by aspirin, of the acute endothelial dysfunction induced by exercise in patients with intermittent claudication. <i>Thrombosis and Haemostasis</i> , 2007, 97, 444-50.	1.8	16
206	Pharmacologic Profile and Therapeutic Potential of NCX 4016, a Nitric Oxide-releasing Aspirin, for Cardiovascular Disorders. <i>Cardiovascular Drug Reviews</i> , 2006, 24, 148-168.	4.4	45
207	Nitric oxide-donating aspirin (NCX 4016): an overview of its pharmacological properties and clinical perspectives. <i>European Journal of Clinical Pharmacology</i> , 2006, 62, 145-154.	0.8	24
208	Selective Cytochrome c Displacement by Phosphate and Ca ²⁺ in Brain Mitochondria. <i>Journal of Membrane Biology</i> , 2006, 212, 199-210.	1.0	5
209	Defective platelet β -N-acetyl hexosaminidase content and release in chronic myeloproliferative disorders. <i>Platelets</i> , 2006, 17, 20-29.	1.1	15
210	Usefulness of lyophilized calibration plasmas for International Normalized Ratio determination with the bovine combined thromboplastin (Thrombotest): results of a collaborative study. <i>Blood Coagulation and Fibrinolysis</i> , 2005, 16, 157-163.	0.5	4
211	β -tubulin in human platelets: not simply a structural cell frame. <i>Blood</i> , 2005, 106, 2229-2230.	0.6	2
212	A novel nitric oxide-releasing statin derivative exerts an antiplatelet/antithrombotic activity and inhibits tissue factor expression. <i>Journal of Thrombosis and Haemostasis</i> , 2005, 3, 2554-2562.	1.9	51
213	Intraplatelet signaling mechanisms of the priming effect of matrix metalloproteinase-2 on platelet aggregation. <i>Journal of Thrombosis and Haemostasis</i> , 2005, 3, 2526-2535.	1.9	65
214	Nitroaspirin plus clopidogrel versus aspirin plus clopidogrel against platelet thromboembolism and intimal thickening in mice. <i>Thrombosis and Haemostasis</i> , 2005, 93, 535-543.	1.8	40
215	Nitric Oxide and its Antithrombotic Action in the Cardiovascular System. <i>Current Drug Targets Cardiovascular & Haematological Disorders</i> , 2005, 5, 65-74.	2.0	31
216	Direct and Irreversible Inhibition of Cyclooxygenase-1 by Nitroaspirin (NCX 4016). <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2005, 315, 1331-1337.	1.3	29

#	ARTICLE	IF	CITATIONS
217	Platelet P-selectin is required for pulmonary eosinophil and lymphocyte recruitment in a murine model of allergic inflammation. <i>Blood</i> , 2005, 105, 2074-2081.	0.6	190
218	Interactions between thrombophilic genetic mutations and clinical bleeding in patients on chronic oral anticoagulant treatment. <i>Haematologica</i> , 2005, 90, 1720-2.	1.7	3
219	Picotamide versus aspirin in diabetic patients with peripheral arterial disease: has David defeated Goliath?. <i>European Heart Journal</i> , 2004, 25, 1769-1771.	1.0	7
220	Binding and Release of Cytochrome c in Brain Mitochondria Is Influenced by Membrane Potential and Hydrophobic Interactions with Cardiolipin. <i>Journal of Membrane Biology</i> , 2004, 198, 43-53.	1.0	28
221	Platelets are necessary for airway wall remodeling in a murine model of chronic allergic inflammation. <i>Blood</i> , 2004, 103, 639-647.	0.6	135
222	Deficiency of thrombin activatable fibrinolysis inhibitor in cirrhosis is associated with increased plasma fibrinolysis. <i>Hepatology</i> , 2003, 38, 230-237.	3.6	124
223	Platelets are essential for leukocyte recruitment in allergic inflammation. <i>Journal of Allergy and Clinical Immunology</i> , 2003, 112, 109-118.	1.5	197
224	Acute, short-term hyperglycemia enhances shear stress-induced platelet activation in patients with type II diabetes mellitus. <i>Journal of the American College of Cardiology</i> , 2003, 41, 1013-1020.	1.2	237
225	NCX4016: a novel antithrombotic agent. <i>Digestive and Liver Disease</i> , 2003, 35, S20-S26.	0.4	9
226	Gastrointestinal safety of NO-aspirin (NCX-4016) in healthy human volunteers: A proof of concept endoscopic study. <i>Gastroenterology</i> , 2003, 124, 600-607.	0.6	211
227	Effect of nitric oxide-donating agents on human monocyte cyclooxygenase-2. <i>Biochemical and Biophysical Research Communications</i> , 2003, 311, 897-903.	1.0	17
228	Title is missing!. <i>Medicine (United States)</i> , 2003, 82, 203-215.	0.4	30
229	MYH9-Related Disease. <i>Medicine (United States)</i> , 2003, 82, 203-215.	0.4	255
230	Inherited thrombocytopenias: a proposed diagnostic algorithm from the Italian Gruppo di Studio delle Piastrine. <i>Haematologica</i> , 2003, 88, 582-92.	1.7	91
231	In vitro assays for evaluating platelet function. , 2002, , 459-470.		11
232	Novel approaches to the treatment of thrombosis. <i>Trends in Pharmacological Sciences</i> , 2002, 23, 25-32.	4.0	67
233	Platelets and allergic diseases. , 2002, , 852-868.		7
234	Prostaglandin Endoperoxides and Thromboxane A2 Activate the same Receptor Isoforms in Human Platelets. <i>Thrombosis and Haemostasis</i> , 2002, 87, 114-121.	1.8	40

#	ARTICLE	IF	CITATIONS
235	Dynamics of the platelet cytoskeleton. , 2002, , 93-103.		4
236	Platelet signalling: calcium. , 2002, , 260-271.		13
237	Platelet signalling: cAMP and cGMP. , 2002, , 290-303.		5
238	Amplification loops: release reaction. , 2002, , 357-368.		3
239	Vascular control of platelet function. , 2002, , 432-456.		8
240	Flow cytometric analysis of platelet function. , 2002, , 485-498.		6
241	Thrombocytosis and thrombocythemia. , 2002, , 623-638.		1
242	Acquired platelet function defects. , 2002, , 689-706.		4
243	Platelets and chemotaxis. , 2002, , 393-411.		2
244	Prostaglandin endoperoxides and thromboxane A2 activate the same receptor isoforms in human platelets. Thrombosis and Haemostasis, 2002, 87, 114-21.	1.8	12
245	Platelets in respiratory disorders and inflammatory conditions. , 2001, , 323-340.		0
246	Platelet pharmacology. , 2001, , 341-366.		0
247	Antiplatelet treatment in peripheral arterial disease. , 2001, , 458-470.		0
248	Platelet priming. , 2001, , 53-78.		0
249	Inherited Disorders and Gene Regulation of Platelet Signal Transduction: The Picture Is Expanding. Thrombosis and Haemostasis, 2001, 86, 728-730.	1.8	2
250	Treatment of Intermittent Claudication with Mesoglycan â€“ A Placebo-controlled, Double-blind Study. Thrombosis and Haemostasis, 2001, 86, 1181-1187.	1.8	16
251	Plateletâ€“leukocyteâ€“endothelium cross talk. , 2001, , 106-123.		3
252	Thrombin Activatable Fibrinolysis Inhibitor (TAFI) Does not Inhibit In Vitro Thrombolysis by Pharmacological Concentrations of t-PA. Thrombosis and Haemostasis, 2001, 85, 661-666.	1.8	21

#	ARTICLE	IF	CITATIONS
253	Salicylates Inhibit T Cell Adhesion on Endothelium Under Nonstatic Conditions: Induction of L-Selectin Shedding by a Tyrosine Kinase-Dependent Mechanism. <i>Journal of Immunology</i> , 2001, 166, 832-840.	0.4	18
254	Low molecular weight heparins prevent thrombin-induced thrombo-embolism in mice despite low anti-thrombin activity. Evidence that the inhibition of feed-back activation of thrombin generation confers safety advantages over direct thrombin inhibition. <i>Haematologica</i> , 2001, 86, 297-302.	1.7	16
255	Inherited disorders and gene regulation of platelet signal transduction: the picture is expanding. <i>Thrombosis and Haemostasis</i> , 2001, 86, 728-30.	1.8	0
256	Platelets Release their Lysosomal Content In Vivo in Humans upon Activation. <i>Thrombosis and Haemostasis</i> , 2000, 83, 157-164.	1.8	79
257	Prevention of pulmonary thromboembolism by NCX 4016, a nitric oxide-releasing aspirin. <i>European Journal of Pharmacology</i> , 2000, 397, 177-185.	1.7	60
258	Involvement of Platelets in Experimental Mouse Trypanosomiasis: Evidence of Mouse Platelet Cytotoxicity against <i>Trypanosoma equiperdum</i> . <i>Experimental Parasitology</i> , 2000, 95, 136-143.	0.5	9
259	Detrimental Effects of High-Dose Dexamethasone in Severe, Refractory, HIV-Related Thrombocytopenia. <i>Annals of Pharmacotherapy</i> , 2000, 34, 1139-1141.	0.9	3
260	Effect of cloricromene on intermittent claudication. A randomized, double-blind, placebo-controlled trial in patients treated with aspirin: effect on claudication distance and quality of life. <i>Vascular Medicine</i> , 2000, 5, 83-89.	0.8	7
261	Platelets. , 2000, , 79-123.		1
262	Splenic irradiation versus splenectomy for severe, refractory HIV-related thrombocytopenia: effects on platelet counts and immunological status. <i>Aids</i> , 2000, 14, 1664-1667.	1.0	5
263	Effect of cloricromene on intermittent claudication. A randomized, double-blind, placebo-controlled trial in patients treated with aspirin: effect on claudication distance and quality of life. <i>Vascular Medicine</i> , 2000, 5, 83-89.	0.8	2
264	Platelets release their lysosomal content in vivo in humans upon activation. <i>Thrombosis and Haemostasis</i> , 2000, 83, 157-64.	1.8	20
265	Assessment of Occlusion of the Vascular Access in Patients on Chronic Hemodialysis: Comparison of Physical Examination with Continuous-Wave Doppler Ultrasound. <i>Nephron</i> , 1999, 82, 7-11.	0.9	10
266	Endogenous Nitric Oxide Acts as a Natural Antithrombotic Agent In Vivo by Inhibiting Platelet Aggregation in the Pulmonary Vasculature. <i>Thrombosis and Haemostasis</i> , 1999, 81, 961-966.	1.8	72
267	Evidence that cytosolic phospholipase A2 is down-regulated by protein kinase C in intact human platelets stimulated with fluoroaluminate. <i>FEBS Letters</i> , 1999, 450, 39-43.	1.3	5
268	PAF levels in saliva are regulated by inflammatory cells. <i>Journal of Periodontal Research</i> , 1998, 33, 237-241.	1.4	9
269	Evidence for separate effects of U73122 on phospholipase C and calcium channels in human platelets. <i>Biochemical Pharmacology</i> , 1998, 56, 1481-1484.	2.0	40
270	Salicylates Inhibit Adhesion and Transmigration of T Lymphocytes by Preventing Integrin Activation Induced by Contact With Endothelial Cells. <i>Blood</i> , 1998, 92, 2389-2398.	0.6	41

#	ARTICLE	IF	CITATIONS
271	Extrapolation of trial results suggests that aspirin is useful in intermittent claudication. <i>BMJ: British Medical Journal</i> , 1998, 317, 1587-1587.	2.4	3
272	Activated human protein C prevents thrombin-induced thromboembolism in mice. Evidence that activated protein c reduces intravascular fibrin accumulation through the inhibition of additional thrombin generation.. <i>Journal of Clinical Investigation</i> , 1998, 101, 667-676.	3.9	95
273	Salicylates Inhibit Adhesion and Transmigration of T Lymphocytes by Preventing Integrin Activation Induced by Contact With Endothelial Cells. <i>Blood</i> , 1998, 92, 2389-2398.	0.6	0
274	Antivasoconstrictor and Antiaggregatory Activities of Picotamide Unrelated to Thromboxane A2 Antagonism. <i>Thrombosis and Haemostasis</i> , 1997, 78, 1385-1391.	1.8	12
275	Platelet Activation Markers in Patients with Peripheral Arterial Disease. <i>Thrombosis and Haemostasis</i> , 1997, 78, 1434-1437.	1.8	35
276	Diabetes Mellitus, Hypercholesterolemia, and Hypertension but Not Vascular Disease Per Se Are Associated With Persistent Platelet Activation In Vivo. <i>Circulation</i> , 1997, 96, 69-75.	1.6	180
277	Platelet activation markers in patients with peripheral arterial disease—a prospective comparison of different platelet function tests. <i>Thrombosis and Haemostasis</i> , 1997, 78, 1434-7.	1.8	9
278	Inhibition of PAF synthesis by stimulated human polymorphonuclear leucocytes with cloricromene, an inhibitor of phospholipase A ₂ activation. <i>British Journal of Pharmacology</i> , 1996, 118, 1351-1358.	2.7	12
279	Protein kinase C inhibitors enhance G-protein induced phospholipase A ₂ activation in intact human platelets. <i>FEBS Letters</i> , 1996, 381, 244-248.	1.3	24
280	Smoking and Impaired Endothelium-Dependent Dilatation. <i>New England Journal of Medicine</i> , 1996, 334, 1674-1674.	13.9	76
281	Platelet glycohydrolase activities: Characterization and release. <i>Cell Biochemistry and Function</i> , 1995, 13, 31-39.	1.4	10
282	New pyridazinone derivatives as inhibitors of platelet aggregation. <i>European Journal of Medicinal Chemistry</i> , 1995, 30, 627-631.	2.6	17
283	Effect of NSAIDs on pepsinogen secretion and calcium mobilization in isolated chief cells. <i>American Journal of Physiology - Renal Physiology</i> , 1995, 268, G968-G978.	1.6	5
284	Original Article: Albumin Prevents TxB ₂ Formation from Thrombin-stimulated Human Platelets by Sequestering the Liberated Arachidonic Acid in the Extracellular Space. <i>Platelets</i> , 1995, 6, 381-387.	1.1	11
285	Thromboxane synthase inhibitors suppress more effectively the aggregation of thromboxane receptor-desensitized than that of normal platelets: role of adenylylcyclase up-regulation. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 1995, 275, 1497-505.	1.3	7
286	Interferon-Alpha Is Effective in the Treatment of HIV-1-Related, Severe, Zidovudine-Resistant Thrombocytopenia: A Prospective, Placebo-controlled, Double-Blind Trial. <i>Annals of Internal Medicine</i> , 1994, 121, 423.	2.0	26
287	Cloricromene inhibits leukotriene formation by human polymorphonuclear leucocytes by suppressing arachidonate release from membrane phospholipids. <i>Biochemical Pharmacology</i> , 1993, 45, 123-130.	2.0	13
288	The effect of defibrotide on thromboembolism in the pulmonary vasculature of mice and rabbits and in the cerebral vasculature of rabbits. <i>British Journal of Pharmacology</i> , 1993, 110, 1565-1571.	2.7	22

#	ARTICLE	IF	CITATIONS
289	Altered platelet function associated with the bronchial hyperresponsiveness accompanying nocturnal asthma. <i>Journal of Allergy and Clinical Immunology</i> , 1993, 91, 894-902.	1.5	78
290	Impaired superoxide anion, platelet-activating factor, and leukotriene B4 synthesis by neutrophils in cirrhosis. <i>Gastroenterology</i> , 1993, 105, 170-177.	0.6	36
291	Platelet Thromboxane A ₂ Receptor Number and Function in Normal and Hypertensive Pregnancy. <i>American Journal of Reproductive Immunology</i> , 1993, 30, 160-166.	1.2	2
292	Prostaglandin E2 potentiates platelet aggregation by priming protein kinase C. <i>Blood</i> , 1993, 82, 2704-2713.	0.6	81
293	Prostaglandin E2 potentiates platelet aggregation by priming protein kinase C. <i>Blood</i> , 1993, 82, 2704-2713.	0.6	1
294	Cloricromene inhibits G-protein-mediated activation of phospholipase A2 in human platelets. <i>Journal of Lipid Mediators</i> , 1993, 7, 253-67.	0.2	3
295	Prostaglandin E2 potentiates platelet aggregation by priming protein kinase C. <i>Blood</i> , 1993, 82, 2704-13.	0.6	18
296	Evidence for a storage pool defect in platelets from cirrhotic patients with defective aggregation. <i>Gastroenterology</i> , 1992, 103, 641-646.	0.6	105
297	Thromboxane does not play a significant role in acute, cold-induced vasoconstriction in Raynaud's phenomenon. Studies with combined thromboxane synthase inhibition and thromboxane receptor antagonism. <i>Thrombosis Research</i> , 1992, 66, 259-264.	0.8	6
298	Activation of phospholipase A2 and β_2 -thromboglobulin release in human platelets: Comparative effects of thrombin and fluoroaluminate stimulation. <i>Lipids and Lipid Metabolism</i> , 1992, 1124, 279-287.	2.6	17
299	Thromboxane synthase inhibitors, thromboxane receptor antagonists and dual blockers in thrombotic disorders. <i>Trends in Pharmacological Sciences</i> , 1991, 12, 158-163.	4.0	117
300	Generation of Arachidonic Acid Metabolites from Stimulated Whole Blood in Patients with Chronic Myeloproliferative Disorders. <i>Acta Haematologica</i> , 1991, 85, 88-92.	0.7	5
301	Red Cell Deformability Alterations in Normal Late Pregnancy: Possible Role of Plasma Components. <i>Gynecologic and Obstetric Investigation</i> , 1991, 32, 213-216.	0.7	2
302	Effect of glyceryl trinitrate on distensibility of peripheral muscular arteries in humans is not mediated by prostaglandins. <i>Cardiovascular Research</i> , 1991, 25, 692-699.	1.8	1
303	Picotamide Protects Mice from Death in a Pulmonary Embolism Model by a Mechanism Independent from Thromboxane Suppression. <i>Thrombosis and Haemostasis</i> , 1990, 64, 080-086.	1.8	35
304	Picotamide protects mice from death in a pulmonary embolism model by a mechanism independent from thromboxane suppression. <i>Thrombosis and Haemostasis</i> , 1990, 64, 80-6.	1.8	11
305	Characterization of N,N ^o -bis(3-Picolyl)-4-Methoxy-Isophtalamide (Picotamide) as a Dual Thromboxane Synthase Inhibitor/Thromboxane A2 Receptor Antagonist in Human Platelets. <i>Thrombosis and Haemostasis</i> , 1989, 61, 479-484.	1.8	73
306	Acetylsalicylic acid, BM 13.177 and picotamide improve the survival of endotoxin-infused rabbits. <i>Thrombosis Research</i> , 1988, 52, 487-492.	0.8	5

#	ARTICLE	IF	CITATIONS
307	Adenylate cyclase activation determines the effect of thromboxane synthase inhibitors on platelet aggregation in vitro. Comparison of platelets from responders and nonresponders. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 1988, 246, 301-7.	1.3	28
308	Choline plasmalogen biosynthesis by transmethylation in human platelets. <i>Thrombosis Research</i> , 1987, 45, 687-693.	0.8	10
309	L-652,343, a novel dual cyclo/lipoxygenase inhibitor, inhibits LTB4-production by stimulated human polymorphonuclear cells but not by stimulated human whole blood. <i>Biochemical Pharmacology</i> , 1987, 36, 3529-3531.	2.0	17
310	In vitro and ex vivo effects of indobufen on red blood cell deformability. <i>European Journal of Clinical Pharmacology</i> , 1987, 32, 207-210.	0.8	8
311	Evidence for Platelet Activation in Allergic Asthma. , 1987, 21, 119-128.		10
312	Dipyridamole Inhibits Leukotriene B4 Synthesis. <i>Thrombosis and Haemostasis</i> , 1987, 57, 235-235.	1.8	9
313	Role of proaggregatory and antiaggregatory prostaglandins in hemostasis. Studies with combined thromboxane synthase inhibition and thromboxane receptor antagonism.. <i>Journal of Clinical Investigation</i> , 1987, 80, 1435-1445.	3.9	101
314	Dipyridamole inhibits leukotriene B4 synthesis. <i>Thrombosis and Haemostasis</i> , 1987, 57, 235.	1.8	3
315	Leukotriene B4 production by stimulated whole blood: Comparative studies with isolated polymorphonuclear cells. <i>Biochemical and Biophysical Research Communications</i> , 1986, 137, 334-342.	1.0	57
316	Mechanism of the Antiplatelet Action of Dipyridamole in Whole Blood: Modulation of Adenosine Concentration and Activity. <i>Thrombosis and Haemostasis</i> , 1986, 55, 012-018.	1.8	108
317	Mechanism of the antiplatelet action of dipyridamole in whole blood: modulation of adenosine concentration and activity. <i>Thrombosis and Haemostasis</i> , 1986, 55, 12-8.	1.8	29
318	Partial isolation and function of the prostacyclin regulating plasma factor. <i>Clinical Science</i> , 1985, 69, 383-393.	1.8	25
319	COMBINING ANTIPLATELET AGENTS: POTENTIATION BETWEEN ASPIRIN AND DIPYRIDAMOLE. <i>Lancet, The</i> , 1985, 325, 937-938.	6.3	11
320	PLATELETS AND ASTHMA. <i>Lancet, The</i> , 1985, 325, 347.	6.3	31
321	THROMBOEMBOLIC COMPLICATIONS AND HAEMOSTATIC CHANGES IN CYCLOSPORIN-TREATED CADAVERIC KIDNEY ALLOGRAFT RECIPIENTS. <i>Lancet, The</i> , 1985, 325, 999-1002.	6.3	210
322	Lack of synergism between dazoxiben and dipyridamole following administration to man. <i>Thrombosis Research</i> , 1985, 37, 231-236.	0.8	3
323	Aspirin, indomethacin and dazoxiben do not affect the fibrinolytic activation induced by venous occlusion. <i>Thrombosis Research</i> , 1985, 40, 161-170.	0.8	15
324	Thromboxane A2 and prostacyclin do not modulate the systemic hemodynamic response to cold in humans. <i>Translational Research</i> , 1985, 106, 534-41.	2.4	5

#	ARTICLE	IF	CITATIONS
325	BM 13.177, A SELECTIVE BLOCKER OF PLATELET AND VESSEL WALL THROMBOXANE RECEPTORS, IS ACTIVE IN MAN. <i>Lancet, The</i> , 1984, 323, 991-994.	6.3	71
326	PROLONGING PROSTACYCLIN PRODUCTION BY NAFAZATROM OR DIPYRIDAMOLE. <i>Lancet, The</i> , 1984, 324, 410-411.	6.3	37
327	Serum albumin enhances the impairment of platelet aggregation with thromboxane synthase inhibition by increasing the formation of prostaglandin D2. <i>Biochemical Pharmacology</i> , 1984, 33, 2083-2088.	2.0	101
328	Thromboxane Synthase Inhibition Combined with Thromboxane Receptor Blockade: A Step Forward in Antithrombotic Strategy?. <i>Thrombosis and Haemostasis</i> , 1984, 52, 364-364.	1.8	44
329	PLATELET INHIBITORY ACTIVITY OF PROSTACYCLIN IN THE PRESENCE OF ERYTHROCYTES AS STUDIED WITH THE IMPEDANCE AGGREGOMETER. <i>British Journal of Haematology</i> , 1984, 57, 171-173.	1.2	5
330	Thromboxane synthase inhibition combined with thromboxane receptor blockade: a step forward in antithrombotic strategy?. <i>Thrombosis and Haemostasis</i> , 1984, 52, 364.	1.8	7
331	Platelet inhibitory activity of prostacyclin in the presence of erythrocytes as studied with the impedance aggregometer. <i>British Journal of Haematology</i> , 1984, 57, 171-3.	1.2	1
332	Cholinephosphotransferase activity in human platelets. <i>Lipids</i> , 1983, 18, 179-185.	0.7	14
333	Thrombolytic Therapy for Thromboembolism of Vertebrobasilar Artery. <i>Angiology</i> , 1983, 34, 561-571.	0.8	89
334	Dipyridamole Inhibits Platelet Aggregation in Whole Blood. <i>Thrombosis and Haemostasis</i> , 1983, 50, 852-856.	1.8	131
335	Dipyridamole inhibits platelet aggregation in whole blood. <i>Thrombosis and Haemostasis</i> , 1983, 50, 852-6.	1.8	32
336	Ultraviolet spectra of membrane-rich human platelet particulates. <i>Research in Experimental Medicine</i> , 1982, 180, 117-125.	0.7	0
337	ERYTHROCYTE DEFORMABILITY CHANGES IN NORMAL PREGNANCY AND PRE-ECLAMPSIA. <i>British Journal of Haematology</i> , 1982, 52, 340-342.	1.2	16
338	Tranexamic acid, intrauterine contraceptive devices and fatal cerebral arterial thrombosis. Case report. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 1982, 89, 681-682.	1.1	42
339	Platelet activation and allergic asthma. <i>New England Journal of Medicine</i> , 1982, 306, 549.	13.9	15
340	Clotting activation after blood transfusion in patients receiving 5-fluorouracil and mitomycin-C treatment. <i>Cancer Chemotherapy and Pharmacology</i> , 1981, 5, 205-206.	1.1	8
341	Intrinsically Defective or Exhausted Platelets in Hairy Cell Leukemia?. <i>Thrombosis and Haemostasis</i> , 1981, 46, 572-572.	1.8	10
342	Effect of pentoxifylline on platelet aggregation. <i>Pharmatherapeutica</i> , 1981, 2, 532-8.	0.2	18

#	ARTICLE	IF	CITATIONS
343	Mucus-secreting 'signet-ring' cells in CSF revealing the site of primary cancer.. Postgraduate Medical Journal, 1980, 56, 868-870.	0.9	9